Endocrine

, Volume 59, Issue 1, pp 30–38 | Cite as

Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis

Meta-Analysis

Abstract

Purpose

To assess the effectiveness and safety of myoinositol for patients with PCOS.

Methods

In this meta-analysis, data from randomized controlled trials are obtained to assess the effects of myoinositol vs. placebo or western medicine in women with PCOS. The study’s registration number is CRD42017064563. The primary outcomes included total testosterone, estradiol (E2) and the homeostatic model assessment (HOMA) of insulin resistance.

Result

Ten trials involving 573 patients were included. The meta-analysis results show that: compared with the control group, myoinositol may improve HOMA index (WMD −0.65; 95% CI −1.02, −0.28; P = 0. 0005) and increase the E2 level (WMD 16.16; 95% CI 2.01, 30.31; P = 0. 03); while there is no enough strong evidence that the myoinositol has an effect on the total testosterone level (WMD −16.11; 95% CI −46.08, 13.86; P = 0. 29).

Conclusion

Based on current evidence, myoinositol may be recommended for the treatment of PCOS with insulin resistance, as well as for improving symptoms caused by decreased estrogen in PCOS.

Keywords

Myoinositol Polycystic ovary syndrome Systematic review Meta-analysis 

Notes

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions

K.Y. and L.Z. contributed equally to this work.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

12020_2017_1442_MOESM1_ESM.rar (172 kb)
Supplementary materials
12020_2017_1442_MOESM2_ESM.doc (62 kb)
PRISMA 2009 Checklist
12020_2017_1442_MOESM3_ESM.pdf (118 kb)
PROSPERO International prospective register of systematic reviews
12020_2017_1442_MOESM4_ESM.docx (19 kb)
Reply to Review Reports
12020_2017_1442_MOESM5_ESM.docx (21 kb)
The individual specific reasons for each excluded study

References

  1. 1.
    R. Azziz, K.S. Woods, R. Reyna, T.J. Key, E.S. Knochenhauer, B.O. Yildiz, The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89, 2745–2749 (2004).  https://doi.org/10.1210/jc.2003-032046 CrossRefPubMedGoogle Scholar
  2. 2.
    Y. Meng, X. Chen, Z. Peng, X. Liu, Y. Sun, S. Dai, Association between high serum homocysteine levels and biochemical characteristics in women with polycystic ovarian syndrome: a systematic review and meta-analysis. PLoS One 11, e0157389 (2016).  https://doi.org/10.1371/journal.pone.0157389 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group., consensus on diagnostic criteria and long-term healthiest related to polycystic ovary syndrome. Fertil. Steril. 81, 19–25 (2004).  https://doi.org/10.1016/j.fertnstert.2003.10.004. Revised 2003Google Scholar
  4. 4.
    R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, S.F. Witchel, Task force on the phenotype of the polycystic ovary syndrome of the androgen excess PCOS society 2009: The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456–488 (2009)CrossRefPubMedGoogle Scholar
  5. 5.
    R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, S.F. Witchel, Androgen excess society 2006.:, Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91, 4237–4245 (2006)CrossRefPubMedGoogle Scholar
  6. 6.
    L.J. Moran, M.L. Misso, R.A. Wild, R.J. Norman, Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 16, 347–363 (2010)CrossRefPubMedGoogle Scholar
  7. 7.
    J. Vague, La différentiation sexuelle. Facteur determinant des formes de l’obesité. Presse Med. 55, 339–340 (1947)PubMedGoogle Scholar
  8. 8.
    A.H. Kissebah, N. Vydelingum, R. Murray, D.J. Evans, A.J. Hartz, R.K. Kalkhoff, P.W. Adams, Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab. 54, 254–260 (1982)CrossRefPubMedGoogle Scholar
  9. 9.
    M.A. Kirschner, E. Samojlik, M. Drejka, E. Szmal, G. Schneider, N. Ertel, Androgen-estrogen metabolism in women with upper body versus lower body obesity. J. Clin. Endocrinol. Metab. 70, 473–479 (1990)CrossRefPubMedGoogle Scholar
  10. 10.
    C.R. Kahn, J.S. Flier, R.S. Bar, J.A. Archer, P. Gorden, M.M. Martin, J. Roth, The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N. Engl. J. Med. 294, 739–745 (1976)CrossRefPubMedGoogle Scholar
  11. 11.
    C. Wu, F. Lin, S. Qiu, Z. Jiang, The characterization of obese polycystic ovary syndrome rat model suitable for exercise intervention. PLoS One 9, e99155 (2014).  https://doi.org/10.1371/journal.pone.0099155 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    J.E. Nestler, J.F. Strauss III, Insulin as an effector of human ovarian and adrenal steroid metabolism. Endocrinol. Metab. Clin. N. Am. 20, 807–823 (1991)Google Scholar
  13. 13.
    J.C. Marshall, A. Dunaif, Should all women with PCOS be treated for insulin resistance? Fertil. Steril. 97, 18–22 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    J.E. Nestler, D. Stovall, N. Akhter, M.J. Iuorno, D.J. Jakubowicz, Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil. Steril. 77, 209–215 (2002)CrossRefPubMedGoogle Scholar
  15. 15.
    V. De Leo, M.C. Musacchio, G. Morgante, P. Piomboni, F. Petraglia, Metformin treatment is effective in obese teenage girls with PCOS. Hum. Reprod. 21, 2252–2256 (2006)CrossRefPubMedGoogle Scholar
  16. 16.
    E. Papaleo, V. Unfer, J.P. Baillargeon, F. Fusi, F. Occhi, L. De Santis, Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles: a prospective, controlled, randomized trial. Fertil. Steril. 91, 1750–1754 (2009)CrossRefPubMedGoogle Scholar
  17. 17.
    D. Costantino, G. Minozzi, E. Minozzi, C. Guaraldi, Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur. Rev. Med. Pharmacol. Sci. 13, 105–110 (2009)PubMedGoogle Scholar
  18. 18.
    G. Donà, C. Sabbadin, C. Fiore, M. Bragadin, F.L. Giorgino, E. Ragazzi, G. Clari, L. Bordin, D. Armanini, Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur. J. Endocrinol. 166, 703–710 (2012).  https://doi.org/10.1530/EJE-11-0840 CrossRefPubMedGoogle Scholar
  19. 19.
    J.J. Deeks, J.P. Higgins, D.G. Altman, in Special Topics in Statistics, ed. by J.P. Higgins, S. Green Cochrane Handbook for Systematic Reviews of Interventions, Chapter 16 (The Cochrane Collaboration, UK, 2011)Google Scholar
  20. 20.
    J.J. Deeks, J.P. Higgins, D.G. Altman, in Assessing Risk of Bias in Included Studies, ed. by J.P. Higgins, S. Green Cochrane Handbook or Systematic Reviews of Interventions Version 5.1.0, Chapter 8 (The Cochrane Collaboration, UK, 2011)Google Scholar
  21. 21.
    J.J. Deeks, J.P. Higgins, D.G. Altman, in Analyzing Data and Undertaking Meta-analyses. ed. by J.P. Higgins, S. Green Cochrane Handbook for Systematic Reviews of Interventions, Chapter 9 (The Cochrane Collaboration, UK, 2011)Google Scholar
  22. 22.
    E. Benelli, S. Del Ghianda, C. Di Cosmo, M. Tonacchera, A combined therapy with Myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int. J. Endocrinol. 2016, 3204083 (2016).  https://doi.org/10.1155/2016/3204083 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    J. Nehra, J. Kaushal, S.R. Singhal, V.S. Gehlaut, A comparative study of myo inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women. Int. J. Pharm. Sci. Res. 8(4), 1664–1670 (2017).  https://doi.org/10.13040/IJPSR.0975-8232 Google Scholar
  24. 24.
    F. Fruzzetti, D. Perini, M. Russo, F. Bucci, A. Gadducci, Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol. Endocrinol. 33, 39–42 (2017)CrossRefPubMedGoogle Scholar
  25. 25.
    P.G. Artini, O.M. Di Berardino, F. Papini, A.D. Genazzani, G. Simi, M. Ruggiero, V. Cela, Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol. Endocrinol. 29, 375–379 (2013).  https://doi.org/10.3109/09513590.2012.743020 CrossRefPubMedGoogle Scholar
  26. 26.
    A.D. Genazzani, C. Lanzoni, F. Ricchieri, V.M. Jasonni, Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol. Endocrinol. 24, 139–144 (2008).  https://doi.org/10.1080/09513590801893232 CrossRefPubMedGoogle Scholar
  27. 27.
    L. Pkhaladze, L. Barbakadze, N. Kvashilava, Myo-Inositol in the treatment of teenagers affected by PCOS. Int. J. Endocrinol. 2016, 1473612 (2016).  https://doi.org/10.1155/2016/1473612 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    S. Gerli, E. Papaleo, A. Ferrari, G.C. Di Renzo, Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur. Rev. Med. Pharmacol. Sci. 11, 347–354 (2007)PubMedGoogle Scholar
  29. 29.
    S. Gerli, M. Mignosa, G.C. Di Renzo, Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur. Rev. Med. Pharmacol. Sci. 7, 151–159 (2003)PubMedGoogle Scholar
  30. 30.
    Y. Loke, D. Price, A. Herxheimer, in Adverse Effects. ed. by J.P. Higgins, S. Green Cochrane Handbook for Systematic Reviews of Interventions. Chapter 14. (Wiley, Chichester, UK, 2008)Google Scholar
  31. 31.
    J.P.A. Ioannidis, S.J.W. Evans, P.C. Gøtzsche et al. Better reporting of harms in randomized trials: an extension of the Consort statement. Ann. Intern. Med. 141, 781–788 (2004)CrossRefPubMedGoogle Scholar
  32. 32.
    A. Mansour, S. Hosseini, B. Larijani, M.R. Mohajeri-Tehrani, Nutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome. EXCLI J. 15, 551–564 (2016).  https://doi.org/10.17179/excli2016-422. eCollection 2016PubMedPubMedCentralGoogle Scholar
  33. 33.
    T.T. Chiu, M.S. Rogers, C. Briton-Jones, C. Haines, Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum. Reprod. 18, 408–416 (2003)CrossRefPubMedGoogle Scholar
  34. 34.
    V. Unfer, G. Carlomagno, E. Papaleo, S. Vailati, M. Candiani, J.P. Baillargeon, Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod. Sci. 21, 854–858 (2014)CrossRefPubMedGoogle Scholar
  35. 35.
    M.J. Iuorno, D.J. Jakubowicz, J.P. Baillargeon et al. Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr. Pract. 8, 417–423 (2002)CrossRefPubMedGoogle Scholar
  36. 36.
    J.E. Nestler, D.J. Jakubowicz, P. Reamer, R.D. Gunn, G. Allan, Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N. Engl. J. Med. 340, 1314–1320 (1999)CrossRefPubMedGoogle Scholar
  37. 37.
    J.P. Baillargeon, M.J. Iuorno, T. Apridonidze, J.E. Nestler, Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. Metab. Syndr. Relat. Disord. 8, 127–136 (2010).  https://doi.org/10.1089/met.2009.0052 CrossRefPubMedGoogle Scholar
  38. 38.
    V. Unfer, J.E. Nestler, Z.A. Kamenov, N. Prapas, F. Facchinetti, Effects of inositol(s) in women with PCOS: A systematic review of randomized controlled trials. Int. J. Endocrinol. 2016, 1849162 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    V. Unfer, G. Carlomagno, G. Dante, F. Facchinetti, Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol. Endocrinol. 28, 509–515 (2012).  https://doi.org/10.3109/09513590.2011.650660 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Hunan University of Chinese MedicineChangshaChina

Personalised recommendations